Nanozyme enabled protective therapy for neurological diseases
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Neuroinflammation and Neurodegeneration Mechanisms · Electrochemical sensors and biosensors
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. The global burden of mental, neurological and substance use disorders: an analysis from the global burden of disease study 201010.1371/journal.pone.0116820 ↗
2. 19 - The Global Burden of Stroke
3. A century of Alzheimer's disease10.1126/science.1132814 ↗
4. Psychosocial difficulties in people with epilepsy: A systematic review of literature from 2005 until 201010.1016/j.yebeh.2012.05.016 ↗
5. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease10.1038/nm1001-1144 ↗
6. ROS and brain diseases: the good, the bad, and the ugly10.1155/2013/963520 ↗
7. The applications of nanozymes in neurological diseases: from mechanism to design10.7150/thno.83370 ↗
8. Nanozyme‐enabled treatment of cardio‐and cerebrovascular diseases10.1002/smll.202204809 ↗
9. Catalytic nanozymes for central nervous system disease10.1016/j.ccr.2020.213751 ↗
10. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)10.1039/C8CS00457A ↗
11. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes10.1039/c3cs35486e ↗
12. Nanozyme: new horizons for responsive biomedical applications10.1039/C8CS00718G ↗
13. Copper-zinc-superoxide dismutase (CuZnSOD), an antioxidant gene from seahorse (Hippocampus abdominalis); molecular cloning, sequence characterization, antioxidant activity and potential peroxidation function of its recombinant protein10.1016/j.fsi.2016.08.052 ↗
14. Design of AgM bimetallic alloy nanostructures (M = Au, Pd, Pt) with Tunable morphology and peroxidase-like activity10.1021/cm100393v ↗
15. Catalase mimic property of Co3O4 nanomaterials with different morphology and its application as a calcium sensor10.1021/am406033q ↗
16. Nanozymes: classification, catalytic mechanisms, activity regulation, and applications10.1021/acs.chemrev.8b00672 ↗
17. Wu, J., et al., Nanomaterials as novel agents for amelioration of Parkinson’s disease. 2021, Nano Today.10.1016/j.nantod.2021.101328 ↗
18. Emerging nanotechnology for treatment of Alzheimer's and Parkinson's dIsease
19. Nanozyme scavenging ROS for prevention of pathologic alpha-synuclein transmission in Parkinson's disease10.1016/j.nantod.2020.101027 ↗
20. A functionalized octahedral palladium nanozyme as a radical scavenger for ameliorating Alzheimer's disease10.1021/acsami.1c06687 ↗
21. Catalytic-enhanced lactoferrin-functionalized Au-Bi2Se3 nanodots for Parkinson's disease therapy via reactive oxygen attenuation and mitochondrial protection10.1002/adhm.202100316 ↗
22. Recent advances in nanozyme research10.1002/adma.201805368 ↗
23. The role of oxidative stress in neurodegenerative diseases10.5607/en.2015.24.4.325 ↗
24. The molecular mechanism of the catalase reaction10.1021/ja9018572 ↗
25. Pharmacological potential of cerium oxide nanoparticles10.1039/c0nr00875c ↗
26. Au@Pt nanostructures as oxidase and peroxidase mimetics for use in immunoassays10.1016/j.biomaterials.2010.09.040 ↗
27. Intrinsic catalytic activity of Au nanoparticles with respect to hydrogen peroxide decomposition and superoxide scavenging10.1016/j.biomaterials.2012.10.010 ↗
28. Mechanisms of the pH dependent generation of hydroxyl radicals and oxygen induced by Ag nanoparticles10.1016/j.biomaterials.2012.06.076 ↗
29. Exploring environment-dependent effects of Pd nanostructures on reactive oxygen species (ROS) using electron spin resonance (ESR) technique: implications for biomedical applications10.1039/C5CP04046A ↗
30. Superoxide dismutase nanozymes: an emerging star for anti-oxidation10.1039/D1TB00720C ↗
31. Self-assembly of multi-nanozymes to mimic an intracellular antioxidant defense system10.1002/anie.201600868 ↗
32. Misfolded CuZnSOD and amyotrophic lateral sclerosis10.1073/pnas.0730423100 ↗
33. SOD1 nanozyme with reduced toxicity and MPS accumulation10.1016/j.jconrel.2016.02.038 ↗
34. A biologically effective fullerene (C-60) derivative with superoxide dismutase mimetic properties10.1016/j.freeradbiomed.2004.07.002 ↗
35. Intrinsic peroxidase-like activity of ferromagnetic nanoparticles10.1038/nnano.2007.260 ↗
36. Collins, D. and J. Dawson, Recent history of heme-containing proteins: advances in structure, functions, and reaction intermediate determination. 2013.10.1016/B978-0-08-097774-4.00306-5 ↗
37. Pecoraro · 2013
38. Optimization of Fe3O4 nanozyme activity via single amino acid modification mimicking an enzyme active site10.1039/C6CC08542C ↗
39. Bioinspired Design of Fe3+-Doped Mesoporous Carbon Nanospheres for Enhanced Nanozyme Activity10.1002/chem.201801010 ↗
40. Depletable peroxidase-like activity of Fe3O4 nanozymes accompanied with separate migration of electrons and iron ions10.1038/s41467-022-33098-y ↗
41. Co₃O₄ nanoparticles with multi-enzyme activities and their application in immunohistochemical assay10.1021/am405009f ↗
42. NIR enhanced peroxidase-like activity of Au@CeO2 hybrid nanozyme by plasmon-induced hot electrons and photothermal effect for bacteria killing10.1016/j.apcatb.2021.120317 ↗
43. Prussian blue nanoparticles as multienzyme mimetics and reactive oxygen species scavengers10.1021/jacs.5b12070 ↗
44. Glutathione peroxidase-like nanozymes: mechanism, classification, and bioapplication
45. The refined structure of the selenoenzyme glutathione peroxidase at 0.2-nm resolution10.1111/j.1432-1033.1983.tb07429.x ↗
46. Glutathione peroxidases10.1016/j.bbagen.2012.11.020 ↗
47. Identification of the dehydroascorbic acid reductase and thioltransferase (Glutaredoxin) activities of bovine erythrocyte glutathione peroxidase10.1006/bbrc.1999.0508 ↗
48. Understanding the role of oxo and peroxido species in the glutathione peroxidase (GPx)-like activity of metal based nanozymes10.1016/j.ica.2018.09.045 ↗
49. Manganese‐based nanozymes: multienzyme redox activity and effect on the nitric oxide produced by endothelial nitric oxide synthase10.1002/chem.201800770 ↗
50. Polypyrrole nanoenzymes as tumor microenvironment modulators to reprogram macrophage and potentiate immunotherapy10.1002/advs.202201703 ↗
51. A platinum–ruthenium hybrid prodrug with multi-enzymatic activities for chemo-catalytic therapy of hypoxic tumors10.1039/D2SC03375E ↗
52. A novel nanozyme based on selenopeptide-modified gold nanoparticles with a tunable glutathione peroxidase activity10.1039/C9RA10262K ↗
53. Persistent regulation of tumor microenvironment via circulating catalysis of MnFe2O4@ metal–organic frameworks for enhanced photodynamic therapy10.1002/adfm.201901417 ↗
54. A redox modulatory Mn3O4 nanozyme with multi-enzyme activity provides efficient cytoprotection to human cells in a Parkinson's disease model10.1002/anie.201708573 ↗
55. Superoxide dismutase mimetic properties exhibited by vacancy engineered ceria nanoparticles10.1039/b615134e ↗
56. Nanoceria exhibit redox state-dependent catalase mimetic activity10.1039/b922024k ↗
57. Ceria-zirconia nanoparticles as an enhanced multi-antioxidant for sepsis treatment10.1002/anie.201704904 ↗
58. Regulating the pro- and anti-oxidant capabilities of bimetallic nanozymes for the detection of Fe10.1039/C9NR10135G ↗
59. Enhanced multiple enzymelike activity of PtPdCu trimetallic nanostructures for detection of Fe2+ and evaluation of antioxidant capability10.1021/acssuschemeng.0c08230 ↗
60. Shape-dependent enzyme-like activity of Co3O4 nanoparticles and their conjugation with his-tagged EGFR single-domain antibody10.1016/j.colsurfb.2017.02.034 ↗
61. Albumin-mediated biomineralization of shape-controllable and biocompatible ceria nanomaterials10.1021/acsami.6b15442 ↗
62. Facet‐dependent biodegradable Mn3O4 nanoparticles for ameliorating Parkinson's disease10.1002/adhm.202101316 ↗
63. Nanoisozymes: crystal‐facet‐dependent enzyme‐mimetic activity of V2O5 nanomaterials10.1002/ange.201800681 ↗
64. Defect engineering in nanozymes10.1016/j.mattod.2021.10.032 ↗
65. Defect‐engineered nanozyme‐linked receptors10.1002/smll.202101907 ↗
66. Targeting microglia for therapy of parkinson's disease by using biomimetic ultrasmall nanoparticles10.1021/jacs.0c09390 ↗
67. Self-protecting biomimetic nanozyme for selective and synergistic clearance of peripheral amyloid-beta in an Alzheimer's disease model10.1021/jacs.0c08395 ↗
68. Polyoxometalate-based nanozyme: design of a multifunctional enzyme for multi-faceted treatment of Alzheimer's disease10.1007/s12274-016-1000-6 ↗
69. In situ analysis of nanoparticle soft corona and dynamic evolution10.1038/s41467-022-33044-y ↗
70. Intracellular activation of bioorthogonal nanozymes through endosomal proteolysis of the protein corona10.1021/acsnano.0c00629 ↗
71. Single-atom catalysts: a new frontier in heterogeneous catalysis10.1021/ar300361m ↗
72. Coordination Number Regulation Of Molybdenum Single-atom Nanozyme Peroxidase-like Specificity10.1016/j.chempr.2020.10.023 ↗
73. Perspectives for single-atom nanozymes: advanced synthesis, functional mechanisms, and biomedical applications10.1021/acs.analchem.0c04084 ↗
74. Current advances on the single‐atom nanozyme and its bio‐applications
75. Single-atom nanozymes: classification, regulation strategy, and safety concerns10.1039/D3TB01644G ↗
76. Oxidative stress in brain aging - Implications for therapeutics of neurodegenerative diseases10.1016/S0197-4580(02)00019-2 ↗
77. Selective neuronal vulnerability to oxidative stress in the brain
78. Multifaceted therapy of nanocatalysts in neurological diseases10.1166/jbn.2021.3063 ↗
79. The neuropathological diagnosis of Alzheimer’s disease10.1186/s13024-019-0333-5 ↗
80. Alzheimer’s disease: experimental models and reality10.1007/s00401-016-1662-x ↗
81. Oxidative stress signalling in Alzheimer's disease10.1016/j.brainres.2004.01.012 ↗
82. Oxidative stress induces intracellular accumulation of amyloid beta-protein (A beta) in human neuroblastoma cells10.1021/bi000169p ↗
83. The role of reactive oxygen species in the pathogenesis of Alzheimer's disease, Parkinson's disease, and Huntington's disease: a mini review10.1155/2016/8590578 ↗
84. Shi · Oxid. Stress Transcr. Regul. Alzheimer’s Dis. · 2007 · 21 · 276
85. OXidative stress as a cause of nigral cell-death in Parkinsons-disease and incidental lewy body disease10.1002/ana.410320714 ↗
86. Dietary iron oxide nanoparticles delay aging and ameliorate neurodegeneration in drosophila10.1002/adma.201503893 ↗
87. Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheimer's disease10.1021/acsnano.5b08045 ↗
88. Mitochondria-targeted TPP-MoS2 with dual enzyme activity provides efficient neuroprotection through M1/M2 microglial polarization in an Alzheimer's disease model10.1016/j.biomaterials.2019.119752 ↗
89. Biopersistence of PEGylated carbon nanotubes promotes a delayed antioxidant response after infusion into the rat hippocampus10.1371/journal.pone.0129156 ↗
90. MOF-encapsulated nanozyme enhanced siRNA combo: Control neural stem cell differentiation and ameliorate cognitive impairments in Alzheimer's disease model10.1016/j.biomaterials.2020.120160 ↗
91. Alzheimer's Disease and the Amyloid-beta Peptide.10.3233/JAD-2010-1221 ↗
92. Ceria/POMs hybrid nanoparticles as a mimicking metallopeptidase for treatment of neurotoxicity of amyloid-beta peptide.10.1016/j.biomaterials.2016.05.005 ↗
93. Cerium oxide caged metal chelator: anti-aggregation and anti-oxidation integrated H2O2-responsive controlled drug release for potential Alzheimer's disease treatment10.1039/c3sc50697e ↗
94. MPTP mouse models of Parkinson's disease: an update
95. Animal models of Parkinson’s disease
96. α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice10.1038/s41467-022-31787-2 ↗
97. Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson's disease10.1016/j.neuron.2022.05.009 ↗
98. TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease10.1016/j.neuron.2021.09.031 ↗
99. PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease10.1126/scitranslmed.aax8891 ↗
100. Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease10.1073/pnas.2011196118 ↗